MedPath

Levothyroxine

Generic Name
Levothyroxine
Brand Names
Eltroxin, Ermeza, Euthyrox, Levo-T, Levothroid, Levoxyl, Np Thyroid, Synthroid, Thyquidity, Tirosint, Unithroid
Drug Type
Small Molecule
Chemical Formula
C15H11I4NO4
CAS Number
51-48-9
Unique Ingredient Identifier
Q51BO43MG4
Background

Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quantities of the thyroid hormones T (tetraiodothyronine or thyroxine) and T (triiodothyronine or Liothyronine), resulting in diminished down-stream effects of these hormones. Without sufficient quantities of circulating thyroid hormones, symptoms of hypothyroidism begin to develop such as fatigue, increased heart rate, depression, dry skin and hair, muscle cramps, constipation, weight gain, memory impairment, and poor tolerance to cold temperatures.

In response to Thyroid Stimulating Hormone (TSH) release by the pituitary gland, a normally functioning thyroid gland will produce and secrete T, which is then converted through deiodination (by type I or type II 5′-deiodinases) into its active metabolite T. While T is the major product secreted by the thyroid gland, T exerts the majority of the physiological effects of the thyroid hormones; T and T have a relative potency of ~1:4 (T4:T3). T and T act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. As a result, many cardiac functions including heart rate, cardiac output, and systemic vascular resistance are closely linked to thyroid status.

Prior to the development of levothyroxine, Thyroid, porcine or desiccated thyroid, used to be the mainstay of treatment for hypothyroidism. However, this is no longer recommended for the majority of patients due to several clinical concerns including limited controlled trials supporting its use. Desiccated thyroid products contain a ratio of T4 to T3 of 4.2:1, which is significantly lower than the 14:1 ratio of secretion by the human thyroid gland. This higher proportion of T3 in desiccated thyroid products can lead to supraphysiologic levels of T3 which may put patients at risk of thyrotoxicosis if thyroid extract therapy is not adjusted according to the serum TSH.

Indication

Levothyroxine is indicated as replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. It is also indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Associated Conditions
Edematous Fibrosclerotic Panniculopathy (Cellulite), Hypothyroidism, Localized Adiposity, Myxedema coma, Euthyroid Goitre, Thyrotropin dependent Well-Differentiated Thyroid Cancer

Bioequivalence Study of Levothyroxine Sodium Tablets 100 mcg

Phase 4
Completed
Conditions
Healthy
Interventions
Drug: Drug Eutirox 100 mcg
First Posted Date
2020-10-05
Last Posted Date
2020-10-05
Lead Sponsor
Tecnoquimicas
Target Recruit Count
80
Registration Number
NCT04573907
Locations
🇦🇷

DominguezLab, Paraná, Entre Ríos, Argentina

Thyroid and Adrenocortical Hormone Replacement in Organ Donors

Not Applicable
Completed
Conditions
Brain Death
Interventions
First Posted Date
2020-08-27
Last Posted Date
2020-08-27
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
199
Registration Number
NCT04528797

Intravenous Thyroxine for Heart-Eligible Organ Donors

Phase 3
Completed
Conditions
Brain Death
Heart Failure
Interventions
Drug: Saline
First Posted Date
2020-06-04
Last Posted Date
2024-01-10
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
838
Registration Number
NCT04415658
Locations
🇺🇸

Lifesharing, San Diego, California, United States

🇺🇸

Texas Organ Sharing Alliance, San Antonio, Texas, United States

🇺🇸

Mid-America Transplant Services, Saint Louis, Missouri, United States

and more 11 locations

The Effect of Thyroid Hormone Therapy on Muscle Mass and Function in Older Adults With Subclinical Hypothyroidism

Phase 4
Completed
Conditions
Subclinical Hypothyroidism
Sarcopenia
Interventions
Drug: Placebo
First Posted Date
2020-04-21
Last Posted Date
2023-05-18
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Target Recruit Count
322
Registration Number
NCT04354896
Locations
🇨🇭

Clinic for General Internal Medicine, Bern University Hospital Bern, Bern, Switzerland

🇳🇱

Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, Netherlands

🇳🇱

Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands

and more 2 locations

Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism

Phase 4
Completed
Conditions
Subclinical Hypothyroidism
Interventions
Other: Placebo
First Posted Date
2020-02-28
Last Posted Date
2023-11-18
Lead Sponsor
VA Office of Research and Development
Target Recruit Count
52
Registration Number
NCT04288115
Locations
🇺🇸

Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR, North Little Rock, Arkansas, United States

Can Levothyroxine Treatment Reduce the Development of Cardio-metabolic Disorder in Subclinical Hypothyroidism?

Phase 1
Conditions
Subclinical hypothyroïdism
Interventions
First Posted Date
2019-11-26
Last Posted Date
2019-11-29
Lead Sponsor
Ain Shams University
Target Recruit Count
40
Registration Number
NCT04178928

Low Dose Euthyrox in Treatments of Paraquat Intoxication.

Phase 4
Conditions
Paraquat Poisoning
Interventions
Drug: Traditional therapy
First Posted Date
2019-10-21
Last Posted Date
2019-10-22
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
80
Registration Number
NCT04132622

A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants

Phase 2
Completed
Conditions
Thyroid Disease
Euthyroid
Thyroid Gland
Thyroid Hormones
Hypothyroidism
Interventions
Drug: Armour® Thyroid
First Posted Date
2019-10-11
Last Posted Date
2024-06-05
Lead Sponsor
Allergan
Target Recruit Count
284
Registration Number
NCT04124705
Locations
🇺🇸

Sponsor Site /ID# 235853, Fort Lauderdale, Florida, United States

🇺🇸

Sponsor Site /ID# 236809, West Palm Beach, Florida, United States

🇺🇸

Sponsor Site /ID# 235032, Atlanta, Georgia, United States

and more 25 locations

Improving White Matter Integrity With Thyroid Hormone

Completed
Conditions
Hypothyroidism
Interventions
First Posted Date
2019-09-23
Last Posted Date
2020-04-10
Lead Sponsor
University of Illinois at Chicago
Target Recruit Count
5
Registration Number
NCT04098991
Locations
🇺🇸

University of Illinois at Chicago, Chicago, Illinois, United States

A Randomized Controlled Trial of Thyroid Hormone Supplementation in Hemodialysis Patients

Not Applicable
Recruiting
Conditions
Hypothyroidism
Hemodialysis
Thyroid; Functional Disturbance
Interventions
First Posted Date
2019-06-06
Last Posted Date
2024-02-29
Lead Sponsor
University of California, Irvine
Target Recruit Count
336
Registration Number
NCT03977207
Locations
🇺🇸

University of California Irvine, Orange, California, United States

© Copyright 2025. All Rights Reserved by MedPath